The biological activity of auranofin: Implications for novel treatment of diseases

Inflammopharmacology

Volumn 20, Issue 6, 2012, Pages 297-306

  Madeira, J M ^a   Gibson, D L ^a   Kean, W F ^b   Klegeris, A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti inflammatory; Anti microbial; Anti parasitic; Anti tumor; Auranofin

Indexed keywords

AURANOFIN; CYCLOSPORIN A; METRONIDAZOLE; TACROLIMUS;

AMEBIASIS; ANGIOGENESIS; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BACTERIAL GROWTH; BACTERIAL INFECTION; BIOLOGICAL ACTIVITY; CANCER THERAPY; CELL PROTECTION; CHRONIC LYMPHATIC LEUKEMIA; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; OVARY CARCINOMA; OXIDATIVE STRESS; PARASITOSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SCHISTOSOMIASIS; TUBERCULOSIS; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIRHEUMATIC AGENTS; AURANOFIN; BACTERIAL INFECTIONS; HUMANS; INFLAMMATION; LEUKEMIA; NEOPLASMS; PARASITIC DISEASES; VIRUS DISEASES;

EID: 84872151251     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0149-1     Document Type: Review

References (75)

1. Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D, Miele AE, Pauly F, Bellelli A (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284:28977-28985
2. Arnason BG (1999) Immunologic therapy of multiple sclerosis. Annu Rev Med 50:291-302
3. Ashino T, Sugiuchi J, Uehara J, Naito-Yamamoto Y, Kenmotsu S, Iwakura Y, Shioda S, Numazawa S, Yoshida T (2011) Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1. J Toxicol Sci 36:635-643
4. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539-545
5. Berners-Price SJ, Filipovska A (2011) Gold compounds as therapeutic agents for human diseases. Metallomics 3:863-873
6. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A, Izmendi D, Gladyshev VN, Salinas G (2008) Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J Biol Chem 283:17898-17907
7. Brown NS, Bicknell R (2001) Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 3:323-327
8. Brown KK, Cox AG, Hampton MB (2010) Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett 584:1257-1262
9. Caroli A, Simeoni S, Lepore R, Tramontano A, Via A (2012) Investigation of a potential mechanism for the inhibition of SmTGR by Auranofin and its implications for Plasmodium falciparum inhibition. Biochem Biophys Res Commun 417: 576-581
10. Champion GD, Graham GG, Ziegler JB (1990) The gold complexes. Baillieres Clin Rheumatol 4:491-534
11. Chiellini C, Casini A, Cochet O, Gabbiani C, Ailhaud G, Dani C, Messori L, Amri EZ (2008) The influence of auranofin, a clinically established antiarthritic gold drug, on bone metabolism: analysis of its effects on human multipotent adipose-derived stem cells, taken as a model. Chem Biodivers 5:1513-1520
12. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900
13. Cox AG, Brown KK, Arner ES, Hampton MB (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/ Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76:1097-1109
14. Debnath A, Parsonage D, Andrade RM, He C, Cobo ER, Hirata K, Chen S, Garcia-Rivera G, Orozco E, Martinez MB, Gunatilleke SS, Barrios AM, Arkin MR, Poole LB, Mckerrow JH, Reed SL (2012) A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target. Nat Med 18:956-960
15. Fauci AS (1996) Host factors and the pathogenesis of HIV-induced disease. Nature 384:529-534
16. Fonteh PN, Keter FK, Meyer D (2010) HIV therapeutic possibilities of gold compounds. Biometals 23:185-196
17. Frears ER, Zhang Z, Blake DR, O'connell JP, Winyard PG (1996) Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 381:21-24
18. Glennas A, Kvien TK, Andrup O, Clarke-Jenssen O, Karstensen B, Brodin U (1997) Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol 36:870-877
19. Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathwaya target for prevention and treatment of cancer. Cancer Lett 206:193-199
20. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52:237-268
21. Han S, Kim K, Kim H, Kwon J, Lee YH, Lee CK, Song Y, Lee SJ, Ha N (2008) Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages. Arch Pharm Res 31:67-74
22. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P (2004) Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 53:209-219
23. Hill KE, Mccollum GW, Boeglin ME, Burk RF (1997) Thioredoxin reductase activity is decreased by selenium deficiency. Biochem Biophys Res Commun 234:293-295
24. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan R, Jones DT, Collins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neurooncology 11:341-347
25. Jackson-Rosario S, Self WT (2009) Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J Bacteriol 191:4035-4040
26. Jackson-Rosario S, Cowart D, Myers A, Tarrien R, Levine RL, Scott RA, Self WT (2009) Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct. J Biol Inorg Chem 14:507-519
27. Jeon KI, Jeong JY, Jue DM (2000) Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 164:5981-5989
28. Jones JS (1998) Life in the 21st century: a vision for all. S Afr Med J 88:674
29. Kean WF (1990) Intramuscular versus oral gold therapy. Baillieres Clin Rheumatol 4:219-246
30. Kean WF, Kean IR (2008) Clinical pharmacology of gold. Inflammopharmacology 16:112-125
31. Kean WF, Forestier F, Kassam Y, Buchanan WW, Rooney PJ (1985) The history of gold therapy in rheumatoid disease. Semin Arthritis Rheu 14:180-186
32. Kean WF, Hart L, Buchanan WW (1997) Auranofin. Br J Rheumatol 36:560-572
33. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66:3859-3868
34. Kim IS, Jin JY, Lee IH, Park SJ (2004) Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br J Pharmacol 142:749-755
35. Kim NH, Lee MY, Park SJ, Choi JS, Oh MK, Kim IS (2007) Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122:607-614
36. Kim NH, Oh MK, Park HJ, Kim IS (2010) Auranofin, a gold(I)- containing antirheumatic compound, activates Keap1/Nrf2 signaling via Rac1/iNOS signal and mitogen-activated protein kinase activation. J Pharmacol Sci 113:246-254
37. Korherr C, Gille H, Schafer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, Brinkmann U (2006) Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 103:4240-4245
38. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, Williams DL (2007) Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med 4:e206
39. Lewis MG, Dafonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, Collins M, Wagner WL, Yalley-Ogunro J, Greenhouse J, Chirullo B, Norelli S, Garaci E, Savarino A (2011) Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 25:1347-1356
40. Lo Vecchio A, Zacur GM (2012) Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28:1-9
41. Mancek-Keber M, Gradisar H, Inigo Pestana M, Martinez De Tejada G, Jerala R (2009) Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J Biol Chem 284:19493-19500
42. Martinez-Gonzalez JJ, Guevara-Flores A, Alvarez G, Rendon-Gomez JL, Del Arenal IP (2010) In vitro killing action of auranofin on Taenia crassiceps metacestode (cysticerci) and inactivation of thioredoxin-glutathione reductase (TGR). Parasitol Res 107:227-231
43. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Rad Biol Med 42:872-881
44. Mckeage MJ, Berners-Price SJ, Galettis P, Bowen RJ, Brouwer W, Ding L, Zhuang L, Baguley BC (2000) Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes. Cancer Chemother Pharmacol 46:343-350
45. Moayeri M, Crown D, Dorward DW, Gardner D, Ward JM, Li Y, Cui X, Eichacker P, Leppla SH (2009) The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS). PLoS Pathog 5:e1000456
46. Nakaya A, Sagawa M, Muto A, Uchida H, Ikeda Y, Kizaki M (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk Res 35:243-249
47. Newman ZL, Sirianni N, Mawhinney C, Lee MS, Leppla SH, Moayeri M, Johansen LM (2011) Auranofin protects against anthrax lethal toxin-induced activation of the Nlrp1b inflammasome. Antimicrob Agents Chemother 55:1028-1035
48. Omata Y, Lewis JB, Lockwood PE, Tseng WY, Messer RL, Bouillaguet S, Wataha JC (2006) Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function. Toxicol In Vitro 20:625-633
49. Otterbein LE, Soares MP, Yamashita K, Bach FH (2003) Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 24:449-455
50. Papp KA, Shear NH (1991) Systemic gold therapy. Clin Dermatol 9:535-551
51. Park SJ, Kim IS (2005) The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br J Pharmacol 146:506-513
52. Park CH, Lee MJ, Ahn J, Kim S, Kim HH, Kim KH, Eun HC, Chung JH (2004) Heat shock-inducedmatrix metalloproteinase (MMP)-1 and MMP-3 are mediated through ERK and JNK activation and via an autocrine interleukin-6 loop. J Invest Dermatol 123:1012-1019
53. Park SJ, Lee AN, Youn HS (2010) TBK1-targeted suppression of TRIF-dependent signaling pathway of toll-like receptor 3 by auranofin. Arch Pharm Res 33:939-945
54. Rabasseda X (2011) A report from the XVIII International AIDS Conference. (July 18-23, 2010-Vienna, Austria). Drugs Today (Barc) 46:945-957
55. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, Majori G, Severini C (2008) New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett 582:844-847
56. Saura R, Matsubara T, Mizuno K (1994) Inhibition of neovascularization in vivo by gold compounds. Rheumatol Int 14:1-7
57. Savioli L, Smith H, Thompson A (2006) Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol 22:203-208
58. Serhan CN, Drazen JM (1997) Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions? J Clin Invest 99:1147-1148
59. Shabani F, Mcneil J, Tippett L (1998) The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by anti-rheumatic drugs. Free Radic Res 28:115-123
60. Shapiro DL, Masci JR (1996) Treatment of HIV associated psoriatic arthritis with oral gold. J Rheumatol 23:1818-1820
61. Simonson LG, Goodman CH, Bial JJ, Morton HE (1988) Quantitative relationship of Treponema denticola to severity of periodontal disease. Infect Immun 56:726-728
62. Stanley BA, Sivakumaran V, Shi S, Mcdonald I, Lloyd D, Watson WH, Aon MA, Paolocci N (2011) Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem 286:33669-33677
63. Stern I, Wataha JC, Lewis JB, Messer RL, Lockwood PE, Tseng WY (2005) Anti-rheumatic gold compounds as sublethal modulators of monocytic LPS-induced cytokine secretion. Toxicol In Vitro 19:365-371
64. Talbot S, Nelson R, Self WT (2008) Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia. Br J Pharmacol 154:940-948
65. Tepperman K, Finer R, Donovan S, Elder RC, Doi J, Ratliff D, Ng K (1984) Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science 225:430-432
66. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M (2006) Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40
67. Van Oosten BW, Lai M, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Hodgkinson S, Polman CH (1996) A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. Mult Scler 1:339-342
68. Walz DT, Dimartino MJ, Griswold DE, Intoccia AP, Flanagan TL (1983) Biologic actions and pharmaco kinetic studies of auranofin. Am J Med 75:90-108
69. Winzeler EA (2008) Malaria research in the post-genomic era. Nature 455:751-756
70. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S (1999) Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103:129-135
71. Yamada R, Sano H, Hla T, Hashiramoto A, Fukui W, Miyazaki S, Kohno M, Tsubouchi Y, Kusaka Y, Kondo M (1999) Auranofin inhibits interleukin-1beta- induced transcript of cyclooxygenase- 2 on cultured human synoviocytes. Eur J Pharmacol 385:71-79
72. Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Investig 107:135-142
73. Yamashita M, Niki H, Yamada M, Watanabe-Kobayashi M, Mue S, Ohuchi K (1997) Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages. Eur J Pharmacol 325:221-227
74. Youn HS, Lee JY, Saitoh SI, Miyake K, Hwang DH (2006) Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Bioch Biophys Res Comm 350:866-871
75. Zakhary R, Poss KD, Jaffrey SR, Ferris CD, Tonegawa S, Snyder SH (1997) Targeted gene deletion of heme oxygenase 2 reveals neural role for carbon monoxide. Proc Natl Acad Sci USA 94:14848-14853